Spinal Stenosis Clinical Trial
— TARGETSOfficial title:
Intravenous Versus Topical Use of Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS) : A Prospective, Randomized, Double Blind, Head-to-head Comparison Study
Multilevel decompression and bone graft fusion is a most effective measure for treating degenerative lumbar spinal diseases. Yet, the surgery is commonly associated with large amount of perioperative blood loss and high demand for homologous blood transfusion. Tranexamic acid (TXA) has been proved as efficient in reducing the gross blood loss in various kinds of surgeries. However, high quality evidence of its efficacy and safety is still lacking in lumbar spinal surgeries. Besides, systemic use of TXA carries the risks of thromboembolic complications such as deep venous thrombosis and pulmonary embolism, thus the optimal drug delivery route of TXA remains undetermined. The aim of this study is to test the non-inferiority of topical TXA application to its intravenous use in multilevel decompression and bone graft fusion surgeries. A prospective, randomized, double-blind, head-to-head comparison study design will be adopted.
Status | Not yet recruiting |
Enrollment | 176 |
Est. completion date | |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - American Society of Anesthesiologists(ASA)classification of physical status I-II. - Aged over 50yrs. - Patients suffering from spinal stenosis or intervertebral disc displacement and require multilevel decompression and bone graft fusion surgeries. - Written informed consent. Exclusion Criteria: - ASA III-IV. - Age= 50yrs. - History of chronic renal dysfunction (preoperative blood creatinine> 120mmol/L), liver dysfunction (preoperative blood aspartate or alanine aminotransferase> 50 units/L) or history of coronary artery disease with stent placement. - Abnormal preoperative coagulation profile (preoperative prothrombin time elongation> 3s, activated partial thromboplastin time elongation> 10s, platelet counts< 100*10^9/L or >400*10^9/L, or INR> 1.4). - Pre-existing anemia (male< 12g/dL, female<11g/dL). - Long-term medications of aspirin and/or other anticoagulants. - Patients known as allergic to TXA. - Patients who have religious and/or other beliefs limiting blood transfusion. - Dura mater laceration and/or unexpected massive bleeding during operation. - Cell saver application during operation. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perioperative Total blood loss (TBL) | TBL= PBV*(hematocrit on postoperative day 3- preoperative hematocrit)/average hematocrit; Predicted blood volume(PBV)= k1* height^3(m)+ k2* weight(kg)+ k3 (female: k1=0.3561, k2=0.03308, k3=0.1833, male: k1=0.3669, k2=0.03219, k3=0.6041) | Since operation initiation till postoperative day 3 (POD3) | No |
Secondary | Visible intraoperative blood loss | Since operation initiation till operation completion, an average of 120min | No | |
Secondary | Visible postoperative blood loss within 24hrs | 0- 24hrs postoperatively | No | |
Secondary | Visible postoperative blood loss within 48hrs | 0- 48hrs postoperatively | No | |
Secondary | Combined visible perioperative blood loss | Combined visible perioperative blood loss= visible intraoperative blood loss + visible postoperative blood loss within 24hrs + visible postoperative blood loss within 48hrs | Since operation initiation till postoperative 48hrs | No |
Secondary | Total postoperative blood loss | Total postoperative blood loss= drainage day1(ml)* drainage Hct day1(%)/blood Hct day1(%)+ drainage day2(ml)* drainage Hct day2(%)/blood Hct day2(%) | 0- 48hrs postoperatively | No |
Secondary | Postoperative hidden blood loss (HBL) | HBL=TBL- combined visible perioperative blood loss | 48hrs postoperatively | No |
Secondary | Postoperative prothrombin time(PT) | Tested at operation completion, postoperative 24hrs and postoperative 48hrs | No | |
Secondary | Postoperative activated partial thromboplastin time(APTT) | Tested at operation completion, postoperative 24hrs and postoperative 48hrs | No | |
Secondary | Postoperative fibrinogen level(Fbg) | Tested at operation completion, postoperative 24hrs and postoperative 48hrs | No | |
Secondary | Postoperative international normalized ratio(INR) | Tested at operation completion, postoperative 24hrs and postoperative 48hrs | No | |
Secondary | Postoperative R time | Tested at operation completion, postoperative 24hrs and postoperative 48hrs, using thromboelastography tests. | No | |
Secondary | Postoperative K time | Tested at operation completion, postoperative 24hrs and postoperative 48hrs, using thromboelastography tests. | No | |
Secondary | Postoperative maximum amplitude (MA) | Tested at operation completion, postoperative 24hrs and postoperative 48hrs, using thromboelastography tests. | No | |
Secondary | Postoperative lysis after 30 minutes(LY 30) | Tested at operation completion, postoperative 24hrs and postoperative 48hrs, using thromboelastography tests. | No | |
Secondary | Postoperative hemoglobin nadir | Since operation completion till postoperative 48hrs | No | |
Secondary | Perioperative transfusion rates | Since operation initiation till postoperative 48hrs | No | |
Secondary | Perioperative transfusion amounts | Since operation initiation till postoperative 48hrs | No | |
Secondary | Length of hospital stay | Length of hospital stay is calculated by subtracting day of admission from day of discharge. | A single inpatient duration since the day of admission till the day of discharge, an average of 1 week | No |
Secondary | Adverse event rates | Adverse events include deep venous thrombosis, myocardial infarction, pulmonary embolism, cerebrovascular disease, impaired liver function, impaired renal function and incisional hematoma/ infection. | Since operation initiation till postoperative 48hrs | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06290908 -
RPE-P/TLIF for Lumbar Spinal Stenosis With Instability
|
||
Withdrawn |
NCT03223701 -
Efficacy of Using Solum IV and BMC With GFC in TLIF
|
Phase 4 | |
Recruiting |
NCT03883022 -
Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery
|
N/A | |
Completed |
NCT02902380 -
The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery
|
N/A | |
Not yet recruiting |
NCT06024785 -
Vertebropexy - Randomized-controlled Trial
|
N/A | |
Not yet recruiting |
NCT06000319 -
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
|
||
Completed |
NCT02558621 -
New Robotic Assistance System for Spinal Fusion Surgery
|
N/A | |
Completed |
NCT02454400 -
Pre-surgery Physiotherapy for Patients With Specific Low Back Pain
|
N/A | |
Completed |
NCT01377623 -
Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion
|
N/A | |
Completed |
NCT00996073 -
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
|
Phase 2 | |
Terminated |
NCT00974623 -
Bone Graft Materials Observational Registry
|
N/A | |
Completed |
NCT00320619 -
Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
|
N/A | |
Completed |
NCT00022776 -
Surgical Versus Nonsurgical Treatment for Spinal Stenosis
|
Phase 3 | |
Completed |
NCT06060821 -
Validity and Reliability of the 2-minute Step Test in Patients With Lumbar Spinal Stenosis
|
||
Recruiting |
NCT04552145 -
Physical Therapy vs Surgical Decompression for Lumbar Spinal Stenosis
|
N/A | |
Active, not recruiting |
NCT04379921 -
Improving Spine Surgical Care With Real-Time Objective Patient Tracking Using the Apple Watch
|
N/A | |
Withdrawn |
NCT04315090 -
Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion
|
||
Completed |
NCT04591249 -
Physical Activity Intervention for Patients Following Lumbar Spine Surgery
|
N/A | |
Recruiting |
NCT04601363 -
Personalized Spine Study Group (PSSG) Registry
|
||
Completed |
NCT04193488 -
Mid-Transverse Process to Pleural (MTP) Block and Erector Spinal Plan (ESP) Block in Spinal Surgery
|
N/A |